Medical device regulation isn’t getting “tougher” in theory, it’s getting tougher in practice, right now, in the form of tighter documentation expectations, deeper traceability demands, and less tolerance for variation at scale. For OEMs, that reality is forcing a hard reassessment of one often-overlooked risk factor, how precision metal components are manufactured, validated, and then reproduced consistently and at volume.
Photo-chemical etching (PCE) is increasingly being adopted as a regulation-aligned manufacturing route because it delivers burr-free, stress-free parts with fine features and stable tolerances, without the heat-affected zones, deformation, tool wear, and secondary finishing steps that can add variability and inspection burden in conventional methods.
For medical manufacturers, fewer downstream corrections also means fewer opportunities to introduce contamination, dimensional drift, or rework-driven nonconformities.
“Regulatory pressure is accelerating a broader shift in how OEMs think about manufacturing risk,” says Jochen Kern, Head of Sales & Marketing at the Micro Component Group. “It’s no longer enough to prove a design works once. You have to prove you can make it the same way (again and again) through scale-up, process change, and supply-chain disruption. PCE is powerful because it’s inherently repeatable and digitally defined.”
The Micro Component Group (uniting micrometal GmbH, HP Etch, Etchform, and Thin Metal Parts (TMP) Inc.) positions itself around precisely these pain points. The Group combines agile sheet-based development routes with micrometal’s world-unique continuous reel-to-reel etching, enabling manufacturers to move from prototype to high-volume production without changing the underlying process logic. This “prototype-to-production continuity” reduces the risk of requalification surprises, one of the most expensive and time-consuming problems in regulated medtech programmes.
Beyond scale-up stability, the Micro Component Group brings a multi-technology ecosystem, including electroforming and laser capability alongside etching, so engineers aren’t forced into a single method when a hybrid route delivers the best compliance and performance outcome. Combined with a European and US footprint, the Group supports supply-chain resilience and local technical collaboration, both increasingly important as OEMs try to de-risk critical components and avoid over-dependence on single-site supply.
“For medical OEMs, the real advantage is not ‘precision’ as a marketing word,” Kern adds. “It’s precision as a system — predictable tolerances, low variation, fewer secondary steps, and production models that can support millions of identical parts. That is what makes regulatory compliance less fragile, and innovation more scalable.”
As regulatory expectations continue to rise, precision metal fabrication is becoming a strategic choice, not a sourcing detail. For manufacturers who haven’t explored PCE, the opportunity is clear. Reduce variability, reduce post-processing, accelerate iteration, and build a more robust path from clinical prototype to commercial production.
Micro Component Group invites medical OEMs and design teams to discuss how application-led PCE can strengthen compliance readiness while enabling next-generation device innovation.
Leave a Reply
You must be logged in to post a comment.